Table 1.
Patient characteristics
| Control (placebo) | Research (cediranib) | |
|---|---|---|
| Patient number | 27 | 25 |
| Age (y) | 44 (25–64) | 42 (24–77) |
| ECOG performance status | ||
| 0 | 14 (19%) | 14 (27%) |
| 1 | 13 (33%) | 11 (21%) |
| Disease site | ||
| Local relapse only | 0 (0%) | 6 (12%) |
| Extra‐pelvic metastases only | 9 (17%) | 6 (12%) |
| Local relapse and extrapelvic metastases | 18 (35%) | 13 (25%) |
| Disease‐free survival after primary therapy | ||
| ≤12 months | 12 (23%) | 14 (27%) |
| >12 months | 15 (29%) | 11 (21%) |
| Histology | ||
| Squamous | 19 (37%) | 17 (33%) |
| Adenocarcinoma | 7 (13%) | 5 (10%) |
| Mixed | 1 (2%) | 2 (4%) |
| Other | 0 (0%) | 1 (2%) |
| Degree of differentiation | ||
| Well | 4 (8%) | 1 (2%) |
| Moderate | 10 (19%) | 10 (19%) |
| Poor | 9 (17%) | 10 (19%) |
| Unknown | 4 (8%) | 4 (8%) |
| Previous lines of treatment | ||
| 0 | 3 (6%) | 2 (4%) |
| 1 | 24 (46%) | 23 (44%) |
| Metastatic sites | ||
| Local | 8 (15%) | 7 (13%) |
| Lung | 8 (15%) | 6 (12%) |
| Liver | 4 (8%) | 3 (6%) |
| Para‐aortic | 10 (19%) | 7 (13%) |
ECOG, Eastern Cooperative Oncology Group